Industry News
Pharmaceutical Industry News
Orca Bio has jumped into the…
Orca Bio has jumped into the commercial market with an FDA approval for Tregzi, a first-of-its-kind allogeneic regulatory T cell-based therapy for blood cancer patients requiring transplants.
AstraZeneca will pay $34 million…
AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce providers to write prescriptions for products paid for by Texas Medicaid.
With more than a decade since the…
With more than a decade since the first FDA biosim approval, strong launches of biologic copies of AbbVie’s Humira, J&J’s Stelara and Regeneron/Bayer’s Eylea are shifting a narrative once focused on lagging uptake of the
As Amgen’s rare disease…
As Amgen’s rare disease medicine Tavneos comes under intensifying pressure from the FDA, the company faces a new hurdle with a leading medical journal’s retraction of the drug’s pivotal study data.
Despite a recent failure as a…
Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma, a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed confidence ahead of its high-stakes first-line readout.
Eli Lilly, Regeneron and Fujifilm…
Eli Lilly, Regeneron and Fujifilm are among the seven companies that have been selected to participate in the FDA's PreCheck Pilot Program, designed to strengthen drug manufacturing and supply chain resilience in the U.S. The
Unicycive is optimistic the…
Unicycive is optimistic the third-party manufacturing facility can meet FDA standards to support an approval, CEO Shalabh Gupta, M.D., said in a statement.
AstraZeneca has impressed oncology…
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. Roche, a familiar sight at the top of PatientView’s cancer
Tara Sparks was just days away…
Tara Sparks was just days away from starting her new job at Novo Nordisk in February 2025 when she gathered with some friends to watch her team, the Philadelphia Eagles, take on reigning Super Bowl
CMI Media Group’s Ad Astra…
CMI Media Group's Ad Astra platform looks to connect siloed pharma marketing technologies, with its initial focus targeting omnichannel orchestration.
A Brukinsa regimen has delivered a…
A Brukinsa regimen has delivered a large progression-free survival benefit in what BeOne Medicines called a “new chemotherapy-free standard” in first-line mantle cell lymphoma.
Four months after Theravance…
Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the Dublin-based company has entered into an agreement to be bought out by
Klick Health has struck its third…
Klick Health has struck its third takeover in 18 months, snapping up Oxford PharmaGenesis to expand its global reach and deepen its scientific expertise.
Sobi’s plan to introduce a…
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA.
The FDA has approved Viridian…
The FDA has approved Viridian Therapeutics’ thyroid eye disease treatment, Lumvoa, initiating competition with Amgen’s blockbuster Tepezza, which is the only other therapy on the market for the eye-bulging autoimmune condition.
The agency spotted seven…
The agency spotted seven observations at Dr. Reddy's Bachupally, Hyderabad, biologics plant following a mid-June inspection.
The European Commission has kicked…
The European Commission has kicked off formal proceedings in an antitrust investigation against Sanofi. The probe surrounds the French drugmaker's marketing of its flu vaccine for at-risk seniors, Efluelda.
As Amgen prepares to defend…
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators recommending that the ANCA-associated vasculitis drug lose its authorization in the European Union after
In the past two weeks, CARsgen won…
In the past two weeks, CARsgen won the world's first approval for a solid tumor CAR-T, a behind-the-scenes look at Pfizer and Innovent Biologics' $10.5 billion cancer deal revealed a less-than-five-month sprint, Daiichi Sankyo's new
Eli Lilly is having a Total Recall…
Eli Lilly is having a Total Recall moment, using cutting-edge technology to bring real, undocumented memories to life as it looks to boost awareness of Alzheimer’s disease.